pharmaceuticals
Wegovy-Maker Novo Nordisk Partners With OpenAI to Speed Drug Development
PolyPeptide Attracts Takeover Interest From Eqt, Kkr, Bloomberg News Reports
Gsk Sees Blockbuster Potential in Targeted Cancer Therapy After Promising Early Data
Bayer US Head Says Tariffs Will Not Affect Its 2026 Forecasts
Novo Nordisk Launches Higher-Dose Wegovy in the United States
Date: April 7, 2026
April 7 (Reuters) - Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States. The 7.2-milligram dose, branded...
British Drug-Cost Watchdog Recommends Use of Novo's Wegovy to Lower Heart Risks
Date: March 31, 2026
April 1 (Reuters) - UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's Wegovy to reduce the risk of serious heart problems or strokes in obese or overweight adults, becoming the...
Lilly Seals up to $7.8 Billion Deal for Centessa in Sleep Disorder Bet
Date: March 31, 2026
By Sneha S K March 31 (Reuters) - Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at up to $7.8 billion as the U.S. drugmaker looks to diversify beyond its metabolic...
Drugmakers Delay Some European Launches With a Wary Eye on Trump's Pricing Policies
Date: March 31, 2026
By Maggie Fick, Bhanvi Satija and Dominique Patton LONDON/PARIS, March 31 (Reuters) - Drugmakers are delaying launches of some new medicines in Europe as the industry grapples with U.S. pressure and...
Eli Lilly Seeks Higher Nhs Drug Prices, Rebate Overhaul to Restart UK Investment, Ft Reports
Date: March 30, 2026
March 30 (Reuters) - Eli Lilly wants the UK to regularly raise NHS drug prices and phase out a multi-billion-pound rebate scheme if it is to resume investment, its international businesses president...
Novo Nordisk Appoints Mars CEO as Board Observer
Date: March 26, 2026
COPENHAGEN, March 26 (Reuters) - Novo Nordisk on Thursday elected Poul Weihrauch, CEO of family-owned U.S. candy and pet food giant Mars, as observer to its board, as the drugmaker seeks to strengthen...